{{medical}}{{Drugbox
| verifiedrevid = 458298378
| IUPAC_name = (2''S'',5''R'',6''R'')-6-{[3-(2,6-dichlorophenyl)-5-methyl-<br />oxazole-4-carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-<br />1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| image = Dicloxacillin.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|dicloxacillin-sodium}}
| MedlinePlus = a685017
| pregnancy_AU = B2
| pregnancy_US = B
| legal_AU = S4
| legal_US = 仅作为处方药
| routes_of_administration = 口服
<!--Pharmacokinetic data-->
| bioavailability = 60 to 80%
| protein_bound = 98%
| metabolism =
| elimination_half-life = 20-30分钟
| excretion = 经尿液
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3116-76-5
| ATC_prefix = J01
| ATC_suffix = CF01
| ATC_supplemental =  {{ATCvet|J51|CF01}}
| PubChem = 18381
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00485
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 17358
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = COF19H7WBK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02348
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4511
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 893
<!--Chemical data-->
| C=19 | H=17 | Cl=2 | N=3 | O=5 | S=1
| molecular_weight = 470.327 g/mol
| SMILES = O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(Cl)cccc1Cl)C)[C@H]4SC3(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YFAGHNZHGGCZAX-JKIFEVAISA-N
}}
'''双氯西林'''（Dicloxacillin）是一种半合成的[[β-内酰胺类抗生素|β-内酰胺类抗生素]]，属于耐酶的半合成[[青霉素|青霉素]]类抗生素<ref name=You2012>{{cite book|author1=尤启冬|author2=etal|year=2012|title=药物化学|edition=第7版|location=北京|publisher=人民卫生出版社|pages=303|ISBN=978-7-117-14434-6}}</ref>，主要治疗由[[革兰氏阳性菌|革兰氏阳性菌]]感染引发的疾病<ref name="rossi">"Dicloxacillin". ''livertox.nih.gov''. Retrieved 2015-11-05.</ref>。双氯西林有多种商品名，比如[[百时美施贵宝|百时美施贵宝]]生产的双氯西林商品名是“Diclocil”<ref>{{cite journal|last1=Miranda-Novales|first1=G|last2=Leaños-Miranda|first2=BE|last3=Vilchis-Pérez|first3=M|last4=Solórzano-Santos|first4=F|title=In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.|journal=Annals of Clinical Microbiology and Antimicrobials|date=2006-10-12|volume=5|pages=25|pmid=17034644|doi=10.1186/1476-0711-5-25|pmc=1617116}}</ref>。

==作用机理==
双氯西林是一种半合成的耐酶青霉素类抗生素，属于[[β-内酰胺类抗生素|β-内酰胺类抗生素]]，结构与[[苯唑西林|苯唑西林]]（Oxacillin）相似<ref name=You2012/><ref name=NCBI/>。双氯西林通过抑制革兰氏阳性菌细胞壁的合成起到将其杀灭的效果。从分子层面上说，双氯西林通过与{{link-en|青霉素结合蛋白|Penicillin binding proteins}}（PBP）结合，抑制组成细菌[[细胞壁|细胞壁]]的[[肽聚糖|肽聚糖]]合成，达到抑制细菌合成细胞壁的目的<ref name=NCBI>{{cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/dicloxacillin|title=Dicloxacillin|publisher=PubChem|language=en}}</ref>。

==药物代谢==

双氯西林主要以未代谢的形式经[[肾|肾]]通过尿液排出，在人体内的半衰期大约是20-30分钟<ref name=DrugBank>{{cite web|url=https://www.drugbank.ca/drugs/DB00713|title=Oxacillin|publisher=DrugBank|language=en}}</ref>。

==临床==

双氯西林主要用于治疗由[[革兰氏阳性菌|革兰氏阳性菌]]感染引发的疾病，使用前需要通过耐药性试验验证细菌有无双氯西林[[抗药性|抗药性]]<ref name="rossi"/><ref name=NCBI/>。

虽然双氯西林是作为一种耐酶青霉素开发的，它也很难被[[β-内酰胺酶|β-内酰胺酶]]（青霉素酶）分解，但目前还是发现了对双氯西林具有抗性的耐药菌菌株<ref>{{cite journal|last1=Rosdahl|first1=VT|last2=Frimodt-Møller|first2=N|last3=Bentzon|first3=MW|title=Resistance to dicloxacillin, methicillin and oxacillin in methicillin-susceptible and methicillin-resistant Staphylococcus aureus detected by dilution and diffusion methods.|journal=APMIS : acta pathologica, microbiologica, et immunologica Scandinavica|date=August 1989|volume=97|issue=8|pages=715–22|pmid=2669854}}</ref>。

==参考文献==
{{reflist}}

{{细胞壁破坏性抗生素}}
[[Category:抗生素|Category:抗生素]]
[[Category:Β-内酰胺类抗生素|Category:Β-内酰胺类抗生素]]